Table 3.
ESBL positivity and antibiotic susceptibility rates (%) for E. coli and K. pneumoniae isolates from HA vs CA IAIs & UTIs
| E. coli ESBL +(n=1,094) | K. pneumoniae ESBL +(n=231) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IAI | UTI | IAI | UTI | |||||||||
| All (n=538) | HA (n=437) | CA (n=95) | All (n=556) | HA (n=378) | CA (n=176) | All (n=122) | HA (n=100) | CA (n=20) | All (n=109) | HA (n=86) | CA (n=23) | |
| IPM | 97.21 | 97.02 | 97.89 *** | 97.02 | 96.95 | 97.16 | 82.79 | 82 | 90 | 87.5 | 87.64 | 86.96 |
| ETP | 90.71 | 91.08 | 88.42 | 91.4 | 90.08 | 94.29 *** | 77.05 | 76 | 85 | 82.14 | 85.39 | 69.57 *** |
| AMK | 93.87 | 94.05 | 92.63 *** | 94.74 | 94.4 | 95.43 ** | 84.43 | 85 | 85 | 88.39 | 88.76 | 86.96 *** |
| TZP | 82.34 | 81.92 | 86.32 | 88.97 | 89.06 | 88.64 | 57.38 | 55 | 75 | 61.61 | 62.92 | 56.52 |
| FOX | 57.81 | 57.67 | 58.95 | 62.35 | 62.34 | 61.93 | 51.64 | 49 | 65 | 60.71 | 64.05 | 47.83 |
| CAZ | 31.97 | 31.58 | 34.74 | 37.19 | 37.91 | 35.43 | 23.77 | 23 | 30 | 24.11 | 28.09 | 8.7 |
| CRO | 0 | 0 | 0 | 1.58 | 1.28 | 2.27 | 0 | 0 | 0 | 1.79 | 2.25 | 0 |
| CTX | 0 | 0 | 0 | 1.05 | 0.76 | 1.71 | 0 | 0 | 0 | 2.68 | 3.37 | 0 |
| FEP | 3.35 | 4.12 | 0 | 3.86 | 3.32 | 5.11 | 3.28 | 3 | 5 | 2.68 | 3.37 | 0 |
| LVX | 28.44 | 29.29 | 25.26 | 25.09 | 24.94 | 24.57 | 37.7 | 37 | 45 | 33.93 | 37.08 | 21.74 |
| CIP | 26.95 | 27.92 | 23.16 | 22.94 | 22.9 | 22.16 | 34.43 | 34 | 40 | 30.36 | 32.58 | 21.74 |
Notes: **P<0.01; ***P<0.001, HA vs CA.
Abbreviations: HA, hospital-acquired; CA, community-acquired; IAI, intraabdominalinfection; UTI, urinary tract infection; IPM, Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam; FOX, Cephalosporins: Cefoxitin; CAZ, Ceftazidime; CRO, Ceftriaxone; CTX, Cefotaxime; FEP, Cefepime; LVX, Fluoroquinolones: Levofloxacin; CIP, Ciprofloxacin.